All AbMole products are for research use only, cannot be used for human consumption.
Combretastatin A4 inhibits tubulin polymerization at the colchicine-binding site of beta-tubulin. Combretastatin A4 has antitumor activity by inhibiting AKT function in human gastric cells. The inhibited AKT activation causes decreased cell proliferation, cell cycle arrest, and reduced in vitro migration/invasiveness and in vivo metastatic ability.
| Cell Experiment | |
|---|---|
| Cell lines | MDA-MB-231, A549, and Hela cells |
| Preparation method | Growing MDA-MB-231, A549, and HeLa cells in DMEM medium (115 units/mL of penicillin G, 115 μg/mL of streptomycin, and 10% fetal bovine serum). Seeding cells in 96-well plates (5000 cells/well) containing 50 μL of growth medium for 24 h. After medium removal, adding 100 μL of fresh medium containing individual analogue compounds at different concentrations to each well and incubating at 37 ℃ for 72 h. After 24 h of culture, supplementing the cells with 50 μL of analogue compounds dissolved in DMSO (less than 0.25% in each preparation). After 72 h of incubation, adding 20 μL of resazurin for 2 h before recording fluorescence at 560 nm (excitation) and 590 nm (emission) using a Victor microtiter plate fluorimeter. Defining the IC50 as the compound concentration required to inhibit cell proliferation by 50% in comparison with cells treated with the maximum amount of DMSO (0.25%) and considered as 100% viability. |
| Concentrations | ~3.8 nM |
| Incubation time | 72 h |
| Animal Experiment | |
|---|---|
| Animal models | FVB/N or nude NMRI female mice bearing NT2 and MDA-MB-231 tumors |
| Formulation | DMSO |
| Dosages | 100 mg/kg |
| Administration | i.p. |
| Molecular Weight | 316.35 |
| Formula | C18H20O5 |
| CAS Number | 117048-59-6 |
| Solubility (25°C) | 100 mM in ethanol 100 mM in DMSO |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related Microtubule Products |
|---|
| CCB02
CCB02 is a selective CPAP-tubulin interaction inhibitor, binding to tubulin and competing for the CPAP binding site of β-tubulin, with an IC50 of 689 nM, and shows potent anti-tumor activity. |
| Lisavanbulin
Lisavanbulin (BAL-101553) is the prodrug of the microtubule targeting agent Avanbulin (BAL 27862). |
| 20-O-Demethyl-AP3
20-O-Demethyl-AP3 is a minor metabolite of Ansamitocin P-3. |
| Lisavanbulin dihydrochloride
Lisavanbulin (BAL-101553) dihydrochloride is the prodrug of the microtubule targeting agent Avanbulin (BAL 27862). |
| Paclitaxel-d5
Paclitaxel-d5 |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
